What You Should Know:
– Fortrea, a global contract research organization (CRO), and Medidata, a Dassault Systèmes company specializing in clinical trial solutions, announced an AI-powered partnership to increase diversity in clinical trials.
– The collaboration aims to leverage Medidata’s AI technology, specifically Medidata AI Intelligent Trials, to increase access to diverse patients in Fortrea-conducted clinical trials.
Increase Diversity in Clinical Trails
This partnership builds on an existing collaboration between the two companies, where Fortrea already utilizes Medidata Rave EDC, a robust system for clinical trial data capture and management. By leveraging AI capabilities from Medidata AI Intelligent Trials, Fortrea will now enhance its ability to:
– Identify diverse patient populations: Medidata’s AI technology provides access to vast data and insights, enabling Fortrea to identify and connect with patient populations that are often underrepresented in clinical trials.
– Optimize study feasibility: By understanding the demographics and characteristics of potential participants, Fortrea can tailor study design and recruitment strategies to achieve diverse enrollment goals.
– Accelerate clinical timelines: Efficient patient recruitment through AI-powered insights can significantly shorten the time it takes to launch and complete clinical trials.
– Make clinical therapies accessible: By ensuring diverse participation, the results of clinical trials will be more representative of the real-world population, ultimately leading to therapies that are effective for a wider range of individuals.
“Fortrea and Medidata share a commitment to advancing clinical trial research. This partnership is poised to reshape the landscape of diversity in clinical trials globally. Together, our solutions support customers in life sciences to accelerate study timelines and make the benefits of clinical therapies more accessible to a diverse spectrum of individuals,” said Fareed Melhem, SVP of Medidata AI.
